CEVR analyzes the benefits, risks and costs of strategies to improve health and health care.

About Us
Data

News & Events

Recent Publications

Specialty Drug Coverage Varies Across Commercial Health Plans In The US

Health Affairs

Chambers JD, Kim DD, Pope EF, Graff JS, Wilkinson CL, Neumann PJ. Specialty Drug Coverage Varies Across Commercial Health Plans In The US. Health Affairs 2018;37(7):1041–7.

QALYs in 2018—Advantages and Concerns

JAMA

Neumann PJ, Cohen JT. QALYs in 2018—Advantages and Concerns. Jama 2018;319(24):2473.

Accelerating Alzheimer's disease drug innovations from the research pipeline to patients

Alzheimers & Dementia

Goldman DP, Fillit H, Neumann P. Accelerating Alzheimers disease drug innovations from the research pipeline to patients. Alzheimers & Dementia 2018;

Excluding patients from transplant due to social support: Results from a national survey of transplant providers

American Journal of Transplantation

Ladin K, Emerson J, Berry K, Butt Z, Gordon EJ, Daniels N, Lavelle TA, Hanto DW. Excluding patients from transplant due to social support: Results from a national survey of transplant providers. American Journal of Transplantation 2018;

Economic value of greater access to bariatric procedures for patients with severe obesity and diabetes

Medical Care

Kim DD, Arterburn DE, Sullivan SD, Basu A. Economic Value of Greater Access to Bariatric Procedures for Patients With Severe Obesity and Diabetes. Medical Care 2018;:1.

A comparison of coverage restrictions for biopharmaceuticals and medical procedures

Value in Health

Chambers J, Pope E, Bungay K, Cohen JT, Ciarametaro M, Dubois R, Neumann PJ. A comparison of coverage restrictions for biopharmaceuticals and medical procedures. Value in Health 2018;21(4):400–6.

Accelerating Alzheimer's disease drug innovations from the research pipeline to patients

Alzheimer's & Dementia

Goldman DP, Fillit H, Neumann P. Accelerating Alzheimers disease drug innovations from the research pipeline to patients. Alzheimers & Dementia 2018;

Cost comparison across heart failure patients with reduced and preserved ejection fractions: Analyses of inpatient decompensated heart failure admissions

International Journal of Cardiology

Olchanski N, Vest A, Cohen JT, Neumann PJ, DeNofrio D. Cost Comparison Across Heart Failure Patients With Reduced And Preserved Ejection Fractions: Analyses Of Inpatient Decompensated Heart Failure Admissions. Journal of the American College of Cardiology 2018;67(13):1469.

America’s “NICE”?

Health Affairs

Neumann PJ, Cohen JT. “America’s “NICE”?, " Health Affairs Blog, March 12, 2018.

A health economics approach to US value assessment frameworks—summary and recommendations of the ISPOR special task force report

Value in Health

Garrison LP, Neumann PJ, Willke RJ. A health economics approach to US value assessment frameworks—summary and recommendations of the ISPOR special task force report [7]. Value in Health 2018;21(2):161–5.

Review of recent US value frameworks—a health economics approach: an ISPOR special task force report

Value in Health

Willke RJ, Neumann PJ, Garrison LP, Ramsey SD. Review of recent US value frameworks—a health economics approach: an ISPOR special task force report [6]. Value in Health 2018;21(2):155–60.

An overview of value, perspective, and decision context—a health economics approach: an ISPOR special task force report

Value in Health

Garrison LP, Pauly MV, Willke RJ, Neumann PJ. An overview of value, perspective, and decision context—a health economics approach: an ISPOR special task force report [2]. Value in Health 2018;21(2):124–30.

A health economics approach to US value assessment frameworks—introduction: an ISPOR special task force report

Value in Health

Neumann PJ, Willke RJ, Garrison LP. A health economics approach to US value assessment frameworks—introduction: an ISPOR special task force report [1]. Value in Health 2018;21(2):119–23.

Cost-effectiveness thresholds: the past, the present and the future

PharmacoEconomics

Thokala P, Ochalek J, Leech AA, Tong T. Cost-Effectiveness Thresholds: the Past, the Present and the Future. PharmacoEconomics 2018;36(5):509–22.

Palivizumab prophylaxis for respiratory syncytial virus: examining the evidence around value

Open Forum Infectious Diseases

Olchanski N, Hansen RN, Pope EF, D'Cruz BN, Fergie J, Goldstein M, Krilov LR, McLaurin KK, Nabrit-Stephens B, Oster G, Schaecher K, Shaya FT, Neumann PJ, Sullivan SD. Palivizumab prophylaxis for respiratory syncytial virus: examining the evidence around value. Open Forum Infectious Diseases 2018;5(3).

The CEVR Team

Our team of experienced, dedicated researchers is led by health economists Peter Neumann and Josh Cohen. Together we produce cutting-edge health care cost-effectiveness research.

Meet the CEVR Team

Our Databases

Our comprehensive databases provide the information individuals and organizations need to analyze the benefits, risks, and costs of strategies to improve health and health care.